Matthew L. Posard
Director at Halozyme Therapeutics, Inc. (HALO)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.6M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 73058,109 held (−1%) | $107.17 | $78K | +3.0% |
| Oct 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 3,30054,809 held (−6%) | $108.45 | $358K | +1.8% |
| Oct 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 1,10053,709 held (−2%) | $109.57 | $121K | +0.8% |
| Oct 2SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 10053,609 held (−0%) | $110.04 | $11K | +0.3% |
| Sep 17SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 3,10074,735 held (−4%) | $106.13 | $329K | +4.0% |
| Sep 17SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 3,00071,735 held (−4%) | $106.83 | $320K | +3.4% |
| Sep 17SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 8,89662,839 held (−12%) | $108.04 | $961K | +2.2% |
| Sep 17SEC | HALOHalozyme Therapeutics, Inc. | Sell Plan | 4,00058,839 held (−6%) | $108.99 | $436K | +1.3% |
- Sell
Director Matthew L. Posard sold $78K of HALO at $107.17 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew L. Posard sold $358K of HALO at $108.45 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew L. Posard sold $121K of HALO at $109.57 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew L. Posard sold $11K of HALO at $110.04 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew L. Posard sold $329K of HALO at $106.13 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew L. Posard sold $320K of HALO at $106.83 — pre-scheduled 10b5-1 plan sale.